These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 29784449)

  • 1. A radiosensitivity gene signature and PD-L1 predict the clinical outcomes of patients with lower grade glioma in TCGA.
    Jang BS; Kim IA
    Radiother Oncol; 2018 Aug; 128(2):245-253. PubMed ID: 29784449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A radiosensitivity gene signature and PD-L1 status predict clinical outcome of patients with invasive breast carcinoma in The Cancer Genome Atlas (TCGA) dataset.
    Jang BS; Kim IA
    Radiother Oncol; 2017 Sep; 124(3):403-410. PubMed ID: 28579282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Change of Soluble Programmed Cell Death-Ligand 1 in Glioma Patients Receiving Radiotherapy and Its Impact on Clinical Outcomes.
    Ding XC; Wang LL; Zhu YF; Li YD; Nie SL; Yang J; Liang H; Weichselbaum RR; Yu JM; Hu M
    Front Immunol; 2020; 11():580335. PubMed ID: 33224142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic relevance of programmed cell death ligand 1 expression in glioblastoma.
    Lee KS; Lee K; Yun S; Moon S; Park Y; Han JH; Kim CY; Lee HS; Choe G
    J Neurooncol; 2018 Feb; 136(3):453-461. PubMed ID: 29147863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Radiosensitivity Gene Signature and PD-L1 Status Predict Clinical Outcome of Patients with Glioblastoma Multiforme in The Cancer Genome Atlas Dataset.
    Jang BS; Kim IA
    Cancer Res Treat; 2020 Apr; 52(2):530-542. PubMed ID: 31801317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and validation of an immune-related gene signature for predicting the radiosensitivity of lower-grade gliomas.
    Yan D; Zhao Q; Du Z; Li H; Geng R; Yang W; Zhang X; Cao J; Yi N; Zhou J; Tang Z
    Sci Rep; 2022 Apr; 12(1):6698. PubMed ID: 35461367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A radiosensitivity gene signature in predicting glioma prognostic via EMT pathway.
    Meng J; Li P; Zhang Q; Yang Z; Fu S
    Oncotarget; 2014 Jul; 5(13):4683-93. PubMed ID: 24970813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
    Wick W; Hartmann C; Engel C; Stoffels M; Felsberg J; Stockhammer F; Sabel MC; Koeppen S; Ketter R; Meyermann R; Rapp M; Meisner C; Kortmann RD; Pietsch T; Wiestler OD; Ernemann U; Bamberg M; Reifenberger G; von Deimling A; Weller M
    J Clin Oncol; 2009 Dec; 27(35):5874-80. PubMed ID: 19901110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of Radiosensitivity Gene Signature and PD-L1 Status Predicts Clinical Outcome of Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma: A Study Based on The Cancer Genome Atlas Dataset.
    Dai D; Guo Y; Shui Y; Li J; Jiang B; Wei Q
    Front Mol Biosci; 2021; 8():775562. PubMed ID: 34970597
    [No Abstract]   [Full Text] [Related]  

  • 10. Programmed Death Ligand 1 Is a Negative Prognostic Marker in Recurrent Isocitrate Dehydrogenase-Wildtype Glioblastoma.
    Pratt D; Dominah G; Lobel G; Obungu A; Lynes J; Sanchez V; Adamstein N; Wang X; Edwards NA; Wu T; Maric D; Giles AJ; Gilbert MR; Quezado M; Nduom EK
    Neurosurgery; 2019 Aug; 85(2):280-289. PubMed ID: 30011045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A five-microRNA signature for individualized prognosis evaluation and radiotherapy guidance in patients with diffuse lower-grade glioma.
    Zhang JH; Hou R; Pan Y; Gao Y; Yang Y; Tian W; Zhu YB
    J Cell Mol Med; 2020 Jul; 24(13):7504-7514. PubMed ID: 32412186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of PD-1 positive cells on initial and secondary resected tumor specimens of newly diagnosed glioblastoma and its implications on patient outcome.
    Miyazaki T; Ishikawa E; Matsuda M; Akutsu H; Osuka S; Sakamoto N; Takano S; Yamamoto T; Tsuboi K; Matsumura A
    J Neurooncol; 2017 Jun; 133(2):277-285. PubMed ID: 28447277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies.
    Garber ST; Hashimoto Y; Weathers SP; Xiu J; Gatalica Z; Verhaak RG; Zhou S; Fuller GN; Khasraw M; de Groot J; Reddy SK; Spetzler D; Heimberger AB
    Neuro Oncol; 2016 Oct; 18(10):1357-66. PubMed ID: 27370400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-1/PD-L1 and immune-related gene expression pattern in pediatric malignant brain tumors: clinical correlation with survival data in Korean population.
    Hwang K; Koh EJ; Choi EJ; Kang TH; Han JH; Choe G; Park SH; Yearley JH; Annamalai L; Blumenschein W; Sathe M; McClanahan T; Jung H; Wang KC; Kim SK; Kim CY
    J Neurooncol; 2018 Sep; 139(2):281-291. PubMed ID: 29730815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isocitrate dehydrogenase 1 Gene Mutation Is Associated with Prognosis in Clinical Low-Grade Gliomas.
    Li MY; Wang YY; Cai JQ; Zhang CB; Wang KY; Cheng W; Liu YW; Zhang W; Jiang T
    PLoS One; 2015; 10(6):e0130872. PubMed ID: 26115094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.
    Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF
    EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequency of mismatch repair protein deficiency and PD-L1 in high-grade gliomas in adolescents and young adults (AYA).
    Almuhaisen G; Alhalaseh Y; Mansour R; Abu-Shanab A; Al-Ghnimat S; Al-Hussaini M
    Brain Tumor Pathol; 2021 Jan; 38(1):14-22. PubMed ID: 32897465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy.
    Qian J; Wang C; Wang B; Yang J; Wang Y; Luo F; Xu J; Zhao C; Liu R; Chu Y
    J Neuroinflammation; 2018 Oct; 15(1):290. PubMed ID: 30333036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients.
    Cheng W; Ren X; Cai J; Zhang C; Li M; Wang K; Liu Y; Han S; Wu A
    Oncotarget; 2015 Oct; 6(30):29285-95. PubMed ID: 26320189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Higher programmed cell death 1 ligand 1 (PD-L1) mRNA level in clear cell renal cell carcinomas is associated with a favorable outcome due to the active immune responses in tumor tissues.
    Ning XH; Gong YQ; He SM; Li T; Wang JY; Peng SH; Chen JC; Liu JY; Qi NN; Guo YL; Gong K
    Oncotarget; 2017 Jan; 8(2):3355-3363. PubMed ID: 27926518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.